Approval · Notice of Compliance 794 · 2002
LIN WARFARIN: Notice of Compliance 794
Issued May 1, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 794
- Date
- May 1, 2002
- Company
- Linson Pharma Co.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- New strengths
- Therapeutic class
- Anticoagulant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIN WARFARIN | 02245817 | — |
| LIN WARFARIN | 02245818 | — |
Medicinal ingredients
- WARFARIN SODIUM 3 MG per TAB
- WARFARIN SODIUM 6 MG per TAB